CollaGenex Pharmaceuticals, Inc. is a company that focuses on creating and distributing advanced medical treatments for the dental and dermatology industries. Established in 1992, the corporation is based in Newtown, Pennsylvania.

Drugs associated with CollaGenex Pharmaceuticals, Inc.

Doxycycline

Target

30S subunit

Mechanism

30S subunit inhibitors

Active Org.

Kaifeng Pharmaceutical (Group) Co., Ltd. [+4]

Originator Org.

Renovaro, Inc.

Active Indication

Rosacea [+3]

Inactive Indication

Neurofibromatoses

Drug Highest PhaseApproved

First Approval Ctry. / Loc.

First Approval Date06 Dec 1967

Doxycycline Hyclate

Target

30S subunit

Mechanism

30S subunit inhibitors

Active Org.

CHARTWELL RX SCIENCES LLC [+4]

Originator Org.

Pfizer Inc.

Active Indication

Anthrax [+22]

Inactive Indication

Lyme Disease [+2]

Drug Highest PhaseApproved

First Approval Ctry. / Loc.

First Approval Date05 Dec 1967

Incyclinide

Target

MMP2 x MMP9

Mechanism

MMP2 inhibitors [+1]

Active Org.-

Originator Org.

Galderma Holding SA

Active Indication-

Inactive Indication

Acne Vulgaris [+6]

Drug Highest PhaseDiscontinued

First Approval Ctry. / Loc.-

First Approval Date-

Clinical Trials associated with CollaGenex Pharmaceuticals, Inc.

NCT00495313 / CompletedPhase 4

Determine the Effects of COL-101 Administered Once Daily With Metronidazole Topical Gel, 1% Versus Doxycycline Hyclate 100 mg Administered Once Daily With Metronidazole Topical Gel, 1% in Patients With Moderate to Severe Rosacea

To compare the safety and efficacy of two treatment regimens: 1) COL-101 and metronidazole gel 1%; 2) Doxycycline hyclate 100 mg and metronidazole gel 1%

Start Date01 Mar 2007

Sponsor / Collaborator

CollaGenex Pharmaceuticals, Inc.

NCT00126399 / CompletedPhase 3

A Clinical Trial to Determine the Effects of 40 Mg Doxycycline Versus a Placebo Control for the Treatment of Rosacea

The objective of this study is to evaluate the safety and efficacy of 40 mg doxycycline controlled-release capsules administered once daily for the treatment of rosacea compared with a placebo.

Start Date01 Jun 2004

Sponsor / Collaborator

CollaGenex Pharmaceuticals, Inc.

NCT00041977 / CompletedPhase 3

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Clinical Trial to Determine the Effects of Doxycycline Hyclate 20 Mg Tablets [Periostat(R)] Administered Twice Daily for the Treatment of Acne Rosacea

The purpose of this study is to determine whether Periostat(R), Doxycycline Hyclate 20 mg Tablets, taken twice daily is effective in reducing the red and white heads and overall redness associated with rosacea.

Start Date01 Jun 2002

Sponsor / Collaborator

CollaGenex Pharmaceuticals, Inc.

100 Clinical Results associated with CollaGenex Pharmaceuticals, Inc.

0 Patents (Medical) associated with CollaGenex Pharmaceuticals, Inc.

Literatures (Medical) associated with CollaGenex Pharmaceuticals, Inc.

01 Jan 2008·Journal of drugs in dermatology : JDDQ4 · MEDICINE

Healthcare utilization and costs of patients with rosacea in an insured population.

Q4 · MEDICINE

Article

Author: Romanowicz, Michael ; Lenhart, Greg ; Stephenson, Judith J ; Del Rosso, James Q

BACKGROUNDRosacea is a chronic, relapsing dermatologic condition that affects an estimated 14 million people in the U.S. However, there is little data in the literature on the healthcare utilization and costs of patients with rosacea in insured populations.METHODSThis retrospective, observational, cohort study used the MarketScan databases to identify a rosacea cohort of patients with medical and prescription drug claims between 2002 and 2005. Inclusion criteria were (1) age 30 years and older, (2) at least one medical claim with a primary or secondary diagnosis of rosacea (ICD-9-CM 695.3), (3) at least one pharmacy claim for a rosacea topical or systemic prescription drug, (4) a 6-month clean period prior to index drug and 12 months continuous enrollment after the index drug. Propensity score matching was used to match the rosacea cohort to a control group of patients without rosacea. Disease severity during the 6-month preperiod was assessed by the Charlson Comorbidity Index (CCI), the Chronic Disease Score (CDS), and the Elixhauser Index (EI). Healthcare utilization rates and costs were determined by the type of care for the 12-month postperiod. Costs were calculated for the 12-month post-period and adjusted to reflect 2005 costs. Healthcare utilization rates and costs were reported for inpatient hospital admissions, physician office visits, emergency room visits, other outpatient services, and outpatient pharmacy prescriptions. Both total healthcare and rosacea-related rates and costs were reported.RESULTSThere were no rosacea-related inpatient admissions and very few emergency department visits. More rosacea patients had a specialist visit than a primary care physician visit. The average number of rosacea-related prescriptions, for all patients, was 3.4 (SD 2.7) per year. Total annual healthcare expenditures for the rosacea patient cohort were $735 more than for the matched controls ($6,458 vs. $5,723). Of the total healthcare costs, annual rosacea-related expenditures were $276; approximately 70% of rosacea-related expenditures were due to prescription drugs. Topical drugs were the index drugs for 77% of rosacea patients with branded metronidazole, which is the most common topical drug. Of the 23% of rosacea patients with an oral index drug, generic antibiotic dosage forms of tetracyclines were the most common oral index drug therapy.CONCLUSIONSThis is the first extensive study of rosacea and its impact on healthcare utilization and costs in an insured population. Although rosacea is a common illness that does not have much financial impact on its sufferers, rosacea patients incurred slightly higher direct total healthcare costs than matched controls.

01 Nov 2005·Infection and ImmunityQ2 · MEDICINE

Metalloproteinase Inhibitors, Nonantimicrobial Chemically Modified Tetracyclines, and Ilomastat BlockBacillus anthracisLethal Factor Activity in Viable Cells

Q2 · MEDICINE

Article

Author: Walker, Stephen G. ; Kocer, Salih S. ; Zerler, Brad ; Simon, Sanford R. ; Golub, Lorne M.

ABSTRACTLethal toxin, produced by the bacteriumBacillus anthracis, is a major contributor to morbidity and mortality in animals and humans who have contracted anthrax. One component of this toxin, lethal factor (LF), proteolytically inactivates members of the mitogen-activated protein kinase kinase (MAPKK or MEK) family. In this study we show that CMT-300, CMT-308, and Ilomastat, agents initially characterized as matrix metalloproteinase inhibitors which are in early stages of development as pharmaceuticals, effectively inhibit the zinc metalloproteinase activity of LF. All three inhibitors, CMT-300, CMT-308, and Ilomastat, inhibit LF-mediated cleavage of a synthetic peptide substrate based on the N-terminal domain of MEKs. Inhibition of LF-mediated MEK proteolysis by all three agents was also achieved using lysates of the human monocytoid line MonoMac 6 as sources of MAPKKs and visualization of the extent of cleavage after separation by sodium dodecyl sulfate-polyacrylamide gel electrophoresis followed by detection by Western blotting. Finally, we have demonstrated inhibition of intracellular MEKs in viable human monocytes and MonoMac 6 cells by these agents after incubation of the cells with a reconstituted preparation of recombinant lethal toxin. All three agents are effective inhibitors when incubated with LF prior to exposure to cells, while the CMTs, but not Ilomastat, are also effective when added after LF has already entered the viable cell targets. These results offer promise for strategies to combat effects of the lethal toxin ofB. anthracis.

01 Feb 2001·Current Medicinal ChemistryQ2 · MEDICINE

A Role for the Anti-Inflammatory Properties of Tetracyclines in the Prevention of Acute Lung Injury

Q2 · MEDICINE

Review

Author: Nieman, G. F. ; Zerler, B. R.

The etiology of inflammatory disorders involves many cellular, plasmatic and humoral pathways of signaling culminating in the production of enzymatic and free radical mediated tissue damage. Multiple redundant pathways of initiation and elusive temporal expression of initiators pose formidable barriers to effective treatment. Nowhere is this more evident than in the adult respiratory distress syndrome (ARDS), a systemic inflammatory disorder leading to pulmonary failure where, despite significant advances in intensive care management, mortality has improved only 10% over the last decade. Tetracyclines, in addition to their anti-microbial properties, exhibit inhibitory activity toward several initiators of the inflammatory cascade and mediators of tissue damage. In this review we discuss how the broad spectrum anti-inflammatory properties of the tetracyclines make them attractive candidates for use in the prevention of acute lung injury.

News (Medical) associated with CollaGenex Pharmaceuticals, Inc.

06 Nov 2007

·www.biospace.com

CollaGenex Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of 2007

NEWTOWN, Pa.--(BUSINESS WIRE)--CollaGenex Pharmaceuticals, Inc. (NASDAQ:CGPI) today reported financial results for the third quarter and nine months ended September 30, 2007. Net revenues were $15.9 million in the third quarter of 2007 compared to $5.6 million in the third quarter of 2006, reflecting significantly higher net product sales of Oracea(R), the only FDA-approved systemic treatment for rosacea. Net sales of Oracea were $13.1 million in the third quarter of 2007 compared to $2.2 million in the third quarter of 2006. Total deductions from gross sales for managed care, government and patient rebates, wholesale distribution fees, trade cash discounts and estimated product returns were 14.7% of Oracea gross sales in the third quarter of 2007. Wholesaler inventories were within the Company’s target range of 3 to 5 weeks of sales.

Financial Statement

100 Deals associated with CollaGenex Pharmaceuticals, Inc.

100 Translational Medicine associated with CollaGenex Pharmaceuticals, Inc.

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 26 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Other

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Doxycycline Hyclate ( 30S subunit )	Periodontitis More	Withdrawn
Incyclinide ( MMP2 x MMP9 )	Acute Lung Injury More	Discontinued
Doxycycline ( 30S subunit )	Rosacea More	Pending
COL-8 ( Collagenase x MMPs )	Diabetic Nephropathies More	Pending
COL-308 ( Cytokine receptors x MMPs x Protease )	Anthrax More	Pending

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis